Kornimate/medical-research-clean huggingface dataset:
dermal cooling system for cryotherapy of common skin conditions

Conditions: Skin Lesion

Summary: prospective, non-randomized, open-label study to evaluate the dermal cooling system for cryotherapy of common skin conditions.

the purpose of this study is to establish that controlled localized cooling with the dermal cooling system will elicit an improvement in the cosmetic appearance of benign superficial lesions associated with common skin conditions that are currently being treated with cryosurgical methods.

Eligibility criteria:
inclusion criteria: 1. male or female subjects \> 18 years of age. 2. subject has benign superficial lesion(s) associated with common skin conditions amenable to cryosurgical treatment including, for example, psoriasis, acne, rosacea, and sebaceous hyperplasia. 3. subject is willing to have up to 40 test sites treated. 4. subject has read and signed a written informed consent form. exclusion criteria: 1. physician prescribed procedures in the area of intended treatment in the previous 6 months (e.g., photodynamic therapy, intense pulsed light therapy, laser surgery). 2. dermatological conditions (e.g. vitiligo, open wounds, infection, pre-cancerous or malignant lesions) in the location of the treatment sites that would, in the professional opinion of the investigator, potentially pose an increased risk to the subject. 3. history of melanoma. 4. known history of illness or adverse reaction to cold insult (e.g., cryoglobulinemia, cold urticaria, paroxysmal cold hemoglobinuria, reynaud's disease). 5. history of abnormal wound healing or abnormal scarring 6. inability or unwillingness to comply with the study requirements. 7. subject is pregnant or planning to become pregnant while enrolled in the study. 8. subject is lactating. 9. current enrollment in a clinical study of any other unapproved investigational drug or device. 10. any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect response or participation in this clinical study, or would pose an increased or unacceptable risk to the subject.
comparing virtual yoga to standard care on insomnia among cancer survivors

Conditions: Insomnia

Summary: this feasibility phase ii randomized controlled trial examines the preliminary efficacy of our standardized four-week yocas©® (yoga for cancer survivors) intervention that is delivered virtually on insomnia and sleep quality in cancer survivors. insomnia can be described as excessive daytime napping, difficulty falling asleep, difficulty staying asleep, or waking up earlier than desired. the vast majority of patients with cancer experience some form of sleep impairment post-treatment. yoga is safe, feasible, and effective for improving insomnia and sleep quality in cancer survivors. however, most of the yoga intervention was delivered in person. with the challenges and the social distancing regulation regarding the covid-19 pandemic, adapting to virtual behavioral intervention is critically important and needed. whether the yoga intervention delivered virtually to survivors provides a similar benefit of improving insomnia and sleep quality is unknown.

primary objective: to compare the effects of virtual yocas©® intervention to standard care on changes in insomnia measured via the insomnia severity index among cancer survivors secondary objective: to compare the effects of virtual yocas©® intervention to standard care on changes in sleep quality measured via the pittsburgh sleep quality index among cancer survivors outline: cancer survivors are randomized to 1 of 2 arms. arm i: standard care: cancer survivors receive their standard care arm ii: yocas©® intervention: cancer survivors participate in 8 virtual yocas sessions (75 minutes/session, 2 times a week for 4 weeks) delivered via the electronic platform (e.g., zoom)

Eligibility criteria:
inclusion criteria: cancer survivors must: * have a confirmed diagnosis of cancer * have received surgery, chemotherapy, and/or radiation therapy * have completed all surgery, chemotherapy, and/or radiation therapy within the last 2 months to 10 years * score ≥4 on a 0-10 sleep screening scale * be at least 18 years of age * be able to read and understand english * be able to provide informed consent * have access to the internet and a smartphone, tablet, and/or computer * have the ability to attend 8 virtual yoga sessions exclusion criteria: cancer survivor must not: * have contraindications to yoga participation * have practiced yoga within the 3 months prior to enrolling in the study * be planning to start yoga on their own during the time they are enrolled in the study * have a confirmed diagnosis of sleep apnea or restless leg syndrome * be receiving any form of treatment for cancer with the exception of hormonal or biologic therapy * have distant metastases
quality of life study for sickle cell patients treated with jobelyn (sorghum bicolor extract)

Conditions: Other Sickle-cell Disorders With Crisis, Unspecified

Summary: the purpose of this study is to determine the antioxidant effect of prolonged use of sorghum bicolor (jobelyn) to increase the level of plasma superoxide dismutase and glutathione reductase in patients with sickle cell disease and to determine if there is any improvement in the quality of life of the patients.

jobelyn is an extract of sorghum bicolor that is popular in nigeria as a herbal food supplement. this extract has been shown to have a high oxygen radical absorbance capacity (orac 37,622micro mole te/g) compared to other botanical preparations 1. a second proven property is its anti inflammatory effect with a selective cox 2 inhibition 2. it has also been shown to correct anaemia induced in experimental rabbit by trypanosome brucei brucei 3. jobelyn is being consumed as a herbal nutritional supplement in many disorders including sickle cell disease in nigeria without complaint in over 15 years. the toxicology profile is impressive with a wide therapeutic range. nigeria is one of the countries with the largest burden of sickle cell disease. it is a chronic genetic disorder that accounts for absenteeism at school and at work place. there is also a significant shortening of the life span of the affected patients. sickle cell anaemia presents with recurrent bone pains and progressive organ damage that affects negatively the quality of life of the patients. available measures that have been in use include use of hydroxyurea, chronic and acute red cell transfusion and haematopoietic stem cell transplantation. these have limitations in terms of adverse effects, cost and availability. the pathogenesis involves intracellular precipitation of the mutant haemoglobin, rigidity of the cell, adhesion of cells to the endothelium. these cause recurrent tissue hypoxia and reperfusion which cause release of reactive oxygen series and agents of inflammation. the extract of sorghum is therefore expected to improve the quality of life of these patients. previous work done, have not investigated the long time effect of the extract on the quality of life of sickle cell patients. this study is therefore designed to compare the quality of life of patients on 500mg daily, 250mg daily and 2mg daily of jobelyn using adjusted standard tools. the secondary outcomes to study are changes in indicators of inflammation and systemic antioxidants in these patients. the study period is 12 months so that the period shall involve all the weather conditions in the region.

Eligibility criteria:
inclusion criteria: 1. age : 14 to 40 years 2. sex: both sexes 3. homozygous for the s gene (ss) exclusion criteria: 1. age below 14 years and above 40 years 2. evidence of organ failure i.e heart failure, renal failure 3. no consent for study 4. poor adherence to treatment and irregular visit to the clinic 5. presence of chronic inflammation 6. pregnancy

Keywords: sickle cell anemia quality of life antioxidant anti inflammatory sorghum bicolor
outcomes of focal ablation for prostate cancer

Conditions: Prostate Cancer

Summary: this study will be designed to define the efficacy and safety of ablative therapies in the management of localized prostate cancer and comprehensively evaluate quality of life outcomes and oncologic control following treatment.

this study will be designed to define the efficacy and safety of ablative therapies in the management of localized prostate cancer and comprehensively evaluate quality of life outcomes and oncologic control following treatment. there are several commercially available standard of care treatments available for local therapy of the prostate. ablative therapies may be delivered via a whole gland or focal approach by systems including cryoablation (ca), brachytherapy, irreversible electroporation (ire), high intensity focused ultrasound (hifu), mri-guided transurethral ultrasound ablation (tulsa) procedure or future novel prostate ablation systems. these are single, outpatient treatments lasting between 2-4 hours and include treatment planning and energy delivery under guidance and are either administered via transperineally approach (cryoablation, ire, brachytherapy) or via the urethral (tulsa-pro) or rectum (hifu). this study protocol will not include experimental therapy and the enrolled subjects will undergo the ablative therapy as part of their standard of care treatment.

Eligibility criteria:
inclusion criteria: * men with histologically confirmed prostate adenocarcinoma diagnosed on prostate biopsy * men with histologically confirmed local recurrence of prostate cancer diagnosed on prostate biopsy and standard of care imaging excluding locoregional or metastatic disease * age 18-90 years. * life expectancy \> 1 year * ability to understand and the willingness to sign a written informed consent. exclusion criteria: * anatomic abnormalities that do not allow for focal ablation * evidence of non-organ confined disease that is not feasible for ablation * has active urinary traction infection

Keywords: focal ablation
comparative study of sugammadex versus neostigmine for reversal of neuromuscular blockade in morbidly obese patients

Conditions: Morbid Obesity; Neuromuscular Blockade

Summary: postoperative residual curarization in the post anaesthesia unit has been associated to complications involving respiratory function and impaired laryngeal and pharyngeal muscles' function. speed of reversal of neuromuscular blockade after administration of sugammadex versus neostigmine has been studied, but up to date no data are available concerning continuous acceleromyography monitoring of adductor pollicis and corrugator supercilii in morbidly obese patients undergoing weight loss surgery. the investigators' aim in this prospective, double-blinded study was to compare train of four ( tof ) values, the presence or absence of clinical criteria of postoperative residual curarization , the dose requirements and the side effects of sugammadex and neostigmine for the reversal of rocuronium induced neuromuscular blockade in patients undergoing laparoscopic or open surgery for morbid obesity.

morbidly obese patients \[ body mass index (bmi) \> 40 kg/m2 \] planned to undergo open or laparoscopic surgery for weight loss will be managed with standardized general anesthesia (intravenous propofol combined with remifentanil and muscle relaxation induced by rocuronium). by the end of the surgery, group a and group e patients will receive sugammadex 2 mg/kg corrected body weight \[corrected body weight(cbw)=ideal body weight(ibw) + 40%(real body weight(rbw)-ideal body weight)\] when t2 arises in adductor pollicis. group c and group g will receive neostigmine 50μg/kg corrected body weight when t2 arises in adductor pollicis. group b and group f patients will receive sugammadex 2 mg/kg ideal body weight when t2 arises in adductor pollicis. group d and group h patients will receive 50μg/kg neostigmine ideal body weight. investigators will proceed in continuous acceleromyography monitoring of adductor pollicis and corrugator supercilii during induction of anaesthesia, surgery, recovery and in the post anaesthesia care unit, recording tof values. total consumption of neuromuscular blocking agent, doses of reversal agents and clinical criteria of post operation residual curarization will also be recorded.

Eligibility criteria:
inclusion criteria: * body mass index (bmi) \>40kg * age \< 60 * patients written consent to participate in the study exclusion criteria: * cardiovascular disease (nyha\>2) * patients refusal to participate in the study * contraindication to epidural catheter placement (e.g anticoagulation, anti- platelets medication) * coexisting neuromuscular disease * history of allergic reaction to neuromuscular blocking agents * history of difficult intubation * creatinine levels \> 159lmol/l
clobazam as adjunctive therapy in paediatric patients aged ≥1 to ≤16 years with dravet syndrome

Conditions: Dravet Syndrome

Summary: the purpose of this study is to investigate the effect on the frequency of tonic-clonic and clonic seizures of clobazam as adjunctive therapy compared to placebo after 16 weeks of treatment in paediatric patients aged ≥1 to ≤16 years with dravet syndrome.


Eligibility criteria:
inclusion criteria: * onset of seizures in the first year of life * history of fever-induced prolonged seizures as determined by the investigator * these may include prolonged (approximately 15 minutes or longer) hemi-clonic seizures * multiple seizure types which may include: * generalised tonic-clonic (required for inclusion) * clonic (required for inclusion) * myoclonic jerks/seizures * history of normal development prior to seizure onset followed by development delay or regression after seizure onset * abnormal eeg consistent with dravet syndrome 2. the patient has a history of approximately 2 tonic-clonic or clonic seizures in 2 weeks 3. the patient is treated with at least 1 but no more than 3 antiepileptic drugs (aeds) \[vagal nerve stimulator (vns) and ketogenic diet will not be considered an aed\] 4. patient has at least 2 seizures during the baseline period of either 2 or 4 weeks exclusion criteria: 1. the patient is taking stiripentol, verapamil, or felbatol. if patients have taken these drugs in the past, they need to have been off drug for 5 half-lives 2. the patient is taking a sodium channel blocker including, but not limited to, phenytoin, fosphenytoin, carbamazepine, oxcarbamazepine, lamotrigine, lacosamide, and rufinamide. if patients have taken these drugs in the past, they need to have been off drug for 5 half-lives 3. the patient is on cannabidiol, medical marijuana, or any drug that contains cannabinoids 4. the patient has received chronic treatment (≥2 weeks for any indication) with a benzodiazepine within at least 5 half-lives prior to screening. rescue therapy for prolonged seizures is allowed 5. the patient has received clobazam within 3 months prior to the screening visit. if the patient has received clobazam in the past, discontinuation must not have been for adverse events or lack of efficacy other protocol-defined inclusion and exclusion criteria may apply.
electroacupuncture combined with antidepressants for post-stroke depression

Conditions: Depression; Stroke

Summary: this is a randomized, assessor-blind, placebo controlled study in post stroke depression patients. subjects receiving antidepressant drug would be assigned to either active or placebo scalp electro-acupuncture treatment, on the hypothesis that acupuncture intervention combined with antidepressants could produce greater therapeutic effects than antidepressants alone.

mood depression is a common and serious consequence of stroke. a large proportion of stroke patients develop post-stroke depression (psd), either in the early or late stages after stroke. although antidepressant agents, represented by selective serotonin reuptake inhibitors (ssris), are recommended as first-line drugs in pharmaco-therapy of psd, its effectiveness is limited and the clinical use is largely hampered due to broad side effects, especially on cardiovascular system. in addition, since stroke patients are often medicated with various classes of drugs, the addition of antidepressant agents may increase risk of drug-drug interactions, resulting in unexpected and unpredictable adverse events. the objective of this proposed study is to determine whether electro-acupuncture (ea) combined with antidepressants could produce significantly greater improvement on depressive symptoms in patients with psd compared to antidepressants alone. in this 4-week, assessor-blind, randomized, controlled study of electro-acupuncture (ea) as additional treatment with the antidepressant drug called fluoxetine (flx), a total of 60 patients with post-stroke depression (psd) will be recruited. the patients will be randomly assigned to flx (10-30 mg/day) combined with active cranial and body acupuncture (n =30) or flx with placebo cranial and active body acupuncture (n =30) (12 sessions, 3 sessions a week). changes in the severity of depressive symptoms over time are measured using depressive scale instruments. clinical response and remission rates are also calculated. the study will be conducted at hku school of chinese medicine, tung wah hospital, and kowloon hospital, hong kong.

Eligibility criteria:
inclusion criteria: * most recently experience an ischemic or hemorrhagic stroke, documented by cerebral computed topographic scanning or magnetic resonance imaging * develop significant depression, with a hamd-17 score of 16 or greater exclusion criteria: * presence of severe aphasia, especially fluent aphasia * presence of severe cognitive dysfunction, indicated the mini-mental state examination (mmse) score of \< 18 * had a history of psychiatric illness other than depression * presence of another chronic disorder, including severe parkinson's disease, cardiac disease, cancers, epilepsy, or chronic alcoholism * impaired hepatic or renal function * have bleeding tendency

Keywords: acupuncture post stroke depression depressive disorder cardiovascular accident stroke apoplexy cva
the relationship between post dural puncture headache and joint laxity

Conditions: Postdural Puncture Headache

Summary: post-spinal headache is divided into 3 according to the severity scale. it is divided into 3 groups as mild, moderate and severe according to the presence of symptoms such as nausea, vomiting, and dizziness that prevent daily activity. it has been reported that csf leakage may be higher due to the weakness of the regional dural sac in primary connective tissue diseases with joint laxity and isolated joint hypermobility. joint laxity is scored according to the level of motion in 5 different joints and a maximum of 9 points is obtained. in this study, it was aimed to investigate whether joint laxity contributes to the development of post-spinal headache by questioning the correlation between joint laxity examination score and postspinal headache in patients with post-spinal headache.

post dural puncture headache (pdph), also known as post lumbar puncture (lp) headache, is a common complication of diagnostic lp. it also can occur following spinal anesthesia or, more commonly, inadvertent dural puncture during attempted epidural catheter placement. the headache is usually positional (worse when upright, better when lying flat) and is often accompanied by neck stiffness, photophobia, nausea, or subjective hearing symptoms. in various studies, common patient risk factors for pdph have included female gender, pregnancy, age 18 to 50 years compared with older or younger ages, and a prior history of headache additionally it has been thought that joint laxity contributes to the development of post dural puncture headache. however, no study has been found in the literature examining this relationship between them. in thıs study it was aimed to investigate the relationship between joint laxity and post dural puncture headache.

Eligibility criteria:
inclusion criteria: * 18-65 age * the patients who develop pdph exclusion criteria: * \ 65 age * the patients refused to participate in the study
clinical research on effectiveness and safety of treatment of severe oligospermia or azoospermia with ufsh

Conditions: Oligospermia; Azoospermia

Summary: the purpose of this study is to determine whether ufsh is effective and safe in the treatment of male patients with severe oligospermia or azoospermia.


Eligibility criteria:
inclusion criteria: * male subjects aged 20\~35. * they accorded with diagnostic criteria of severe oligospermia or azoospermia. * they had'nt been treated with drug which could improve sperm count and quality one month before observation，otherwise,they should have a elution for 1 month before the study. exclusion criteria: * gram-positive bacteria ,chlamydia trachomatis,ureaplasmaurealyticum,or mycoplasma hominis were detected in their semen. * subjects addicted to drug，tobacco，or alcohol. * subjects had heat,chemicals,radioactive material,or toxic contact history within a year. * subjects were under treatment of gonadotropin,anabolic steroid,chemotherapeutic drugs,or nonsteroidal anti-inflammatory drugs . * subjects combined with cardiovascular, liver, kidney ,or hematopoietic system severe primary disease,or mental disease. * subjects were allergic or on ufsh allergy,or under the treatment of other drugs for infertility . * subjects did not meet the inclusion criteria, did not according to the prescribed medication, were unable to judge the efficacy ,had incomplete information, or affected the efficacy or safety judgment. * subjects were ihh patients

Keywords: infertility
pilot evaluation of platelet rich fibrin matrix (prfm) for the correction of nasolabial folds

Conditions: Nasolabial Folds

Summary: platelets are a component of blood, which contain factors which can enhance wound healing. this study proposes to evaluate the clinical response of laugh lines treated with a concentrated preparation of the subject's own platelets injected into or under the skin by taking serial photographs of the subject's face over a 12 week period. also, the same preparation will be injected into or under the skin of the arm near the elbows, and serial biopsies will be taken over a 12 week period.


Eligibility criteria:
inclusion criteria: * healthy adults * aged 25- 75 years * with moderate to severe nasolabial folds exclusion criteria: * pregnant * allergy to local anesthetics * history of bleeding disorder * active infection at the treatment site * injectable filler in the nasolabial folds within past year

Keywords: nasolabial folds platelet rich plasma fibrin matrix facial rhytids dermal filler
high dose dexamethasone vs. conventional dose prednisolone in adult itp

Conditions: Idiopathic Thrombocytopenic Purpura

Summary: to determine the long term effects of pulse high dose dexamethasone and conventional dose prednisolone in treatment of adult patients with itp.

patients will be randomized to one of two study arms: dexamethasone 40 mg po daily for 4 consecutive days. if the platelet count drops below 30x109/l after response within 6 months, another four-day course of dexamethasone will be given, followed by 15 mg of prednisone daily, with gradual tapering (arm 1). prednisone 1 mg/kg po daily for 4-8 weeks, the drug is then decreased slowly over another few weeks (arm 2).

Eligibility criteria:
inclusion criteria : * a true thrombocytopenia on blood smear * adequate megakaryopoiesis on bone marrow examination * the absence of clinically apparent associated conditions or cause of thrombocytopenia * age over 16 years * a platelet count of less than 30x109/l exclusion criteria : * previous treatment for itp. * other causes of thrombocytopenia such as hiv infection, lymphproliferative disease, liver disease, or definite sle. * patients with life threatening bleeding and pregnant women should be excluded.

Keywords: itp